Arbutus Biopharma
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ABUS and other ETFs, options, and stocks.About ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).
ABUS Key Statistics
Stock Snapshot
The current Arbutus Biopharma(ABUS) stock price is $4.49, with a market capitalization of 876.72M. The stock trades at a price-to-earnings (P/E) ratio of -24.80.
As of 2026-04-15, Arbutus Biopharma(ABUS) stock has fluctuated between $4.35 and $4.80. The current price stands at $4.49, placing the stock +3.1% above today's low and -6.6% off the high.
The Arbutus Biopharma(ABUS)'s current trading volume is 2.95M, compared to an average daily volume of 1.47M.
In the last year, Arbutus Biopharma(ABUS) shares hit a 52-week high of $5.10 and a 52-week low of $2.94.
In the last year, Arbutus Biopharma(ABUS) shares hit a 52-week high of $5.10 and a 52-week low of $2.94.
ABUS News
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Arbutus Biopharma (ABUS) announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B. Unlock hedge fund-le...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.